SYS6088
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 06, 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=140 | Not yet recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
First-in-human • New P1/2 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1